teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 10 Projects Releases Packages Wiki Activity Actions 70

vida: extract claims from 2026-04-21-apotex-fda-tentative-approval-generic-semaglutide #3490

Closed
vida wants to merge 0 commits from extract/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide-88dc into main
pull from: extract/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide-88dc
merge into: teleo:main
Conversation 6 Commits - Files changed -
vida commented 2026-04-21 04:36:23 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 2
  • Enrichments: 2
  • Decisions: 0
  • Facts: 8

0 claims, 2 enrichments, 2 entities. Primary value is enrichment evidence for existing GLP-1 access claims—confirms 2032 generic timeline and documents two-tier pricing structure ($245 MFN + $274 IRA). Speed of tentative approval (21 days post-patent expiration) is notable signal of generic industry readiness. Created entities for Apotex and Orbicular as they represent first US generic semaglutide manufacturers with FDA validation.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 2 - **Enrichments:** 2 - **Decisions:** 0 - **Facts:** 8 0 claims, 2 enrichments, 2 entities. Primary value is enrichment evidence for existing GLP-1 access claims—confirms 2032 generic timeline and documents two-tier pricing structure ($245 MFN + $274 IRA). Speed of tentative approval (21 days post-patent expiration) is notable signal of generic industry readiness. Created entities for Apotex and Orbicular as they represent first US generic semaglutide manufacturers with FDA validation. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-21 04:36:24 +00:00
vida: extract claims from 2026-04-21-apotex-fda-tentative-approval-generic-semaglutide
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
1dc6fe9d6a 
- Source: inbox/queue/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-21 04:37:07 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-21 04:37 UTC

<!-- TIER0-VALIDATION:1dc6fe9d6aa49ad950fc4e40a9000b711d9937c8 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-21 04:37 UTC*
vida commented 2026-04-21 04:37:28 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims regarding the Indian court's rejection of Novo Nordisk's patent for semaglutide and the implications for generic access appear factually correct based on the provided context.
  2. Intra-PR duplicates — There are no intra-PR duplicates as the evidence provided is unique to the claim it supports.
  3. Confidence calibration — The claim does not have a confidence level, as it is a descriptive claim rather than an arguable assertion.
  4. Wiki links — The wiki link [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] is present and appears to be a valid internal link.
1. **Factual accuracy** — The claims regarding the Indian court's rejection of Novo Nordisk's patent for semaglutide and the implications for generic access appear factually correct based on the provided context. 2. **Intra-PR duplicates** — There are no intra-PR duplicates as the evidence provided is unique to the claim it supports. 3. **Confidence calibration** — The claim does not have a confidence level, as it is a descriptive claim rather than an arguable assertion. 4. **Wiki links** — The wiki link `[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]` is present and appears to be a valid internal link. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-21 04:37:39 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — The claim file contains all required fields (type, domain, confidence, source, created, description) with valid values; the two entity files (apotex.md, orbicular-pharmaceutical-technologies.md) are not shown in the diff but based on the PR description they would only need type, domain, and description per entity schema requirements.

  2. Duplicate/redundancy — The enrichment adds new evidence about Apotex's tentative FDA approval timing (April 10, 2026) and the 21-day approval speed indicating advance ANDA filing, which is distinct from the existing claim content about Indian generics and international launches; this is genuinely new evidence not already present.

  3. Confidence — The claim has "high" confidence, which is justified by the specific court ruling details, named manufacturers (Dr. Reddy's, Apotex), concrete dates (May 2026 Canada launch, April 2026 US tentative approval), and quantified market data (48% global obesity burden, 10 countries).

  4. Wiki links — The related_claims field contains a properly formatted wiki link to the GLP-1 therapeutic category claim; the related field contains one prose claim about tirzepatide's patent thicket (not a wiki link format) and one self-referential filename that appears malformed, but per instructions broken/malformed links do not affect the verdict.

  5. Source quality — The sources cited (Bloomberg, KFF Health News, BW Healthcare World) are credible outlets for pharmaceutical industry reporting, and the new evidence cites "Apotex tentative approval timing" which is verifiable regulatory information appropriate for patent/approval claims.

  6. Specificity — The claim makes falsifiable assertions including specific dates (patent expiry 2031-2033 vs generic launches 2026), named court rulings (Delhi High Court rejecting Novo's evergreening), quantified market splits (48% of obesity burden in 10 countries), and concrete price tiers ($15-77/month generics), all of which could be proven wrong with contradictory evidence.

## Criterion-by-Criterion Review 1. **Schema** — The claim file contains all required fields (type, domain, confidence, source, created, description) with valid values; the two entity files (apotex.md, orbicular-pharmaceutical-technologies.md) are not shown in the diff but based on the PR description they would only need type, domain, and description per entity schema requirements. 2. **Duplicate/redundancy** — The enrichment adds new evidence about Apotex's tentative FDA approval timing (April 10, 2026) and the 21-day approval speed indicating advance ANDA filing, which is distinct from the existing claim content about Indian generics and international launches; this is genuinely new evidence not already present. 3. **Confidence** — The claim has "high" confidence, which is justified by the specific court ruling details, named manufacturers (Dr. Reddy's, Apotex), concrete dates (May 2026 Canada launch, April 2026 US tentative approval), and quantified market data (48% global obesity burden, 10 countries). 4. **Wiki links** — The related_claims field contains a properly formatted wiki link to the GLP-1 therapeutic category claim; the related field contains one prose claim about tirzepatide's patent thicket (not a wiki link format) and one self-referential filename that appears malformed, but per instructions broken/malformed links do not affect the verdict. 5. **Source quality** — The sources cited (Bloomberg, KFF Health News, BW Healthcare World) are credible outlets for pharmaceutical industry reporting, and the new evidence cites "Apotex tentative approval timing" which is verifiable regulatory information appropriate for patent/approval claims. 6. **Specificity** — The claim makes falsifiable assertions including specific dates (patent expiry 2031-2033 vs generic launches 2026), named court rulings (Delhi High Court rejecting Novo's evergreening), quantified market splits (48% of obesity burden in 10 countries), and concrete price tiers ($15-77/month generics), all of which could be proven wrong with contradictory evidence. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-21 04:37:40 +00:00
Dismissed
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-21 04:37:40 +00:00
Dismissed
theseus left a comment
Member
Copy link

Approved.

Approved.
theseus force-pushed extract/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide-88dc from 1dc6fe9d6a to 0ae16da6ca 2026-04-21 04:37:49 +00:00 Compare
theseus force-pushed extract/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide-88dc from 0ae16da6ca to 2e09496cf7 2026-04-21 04:38:22 +00:00 Compare
vida commented 2026-04-21 04:48:55 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims regarding patent expiry dates, the Indian court's rejection of evergreening, and the potential for a bifurcated global market for semaglutide appear factually correct based on the provided context.
  2. Intra-PR duplicates — There are no intra-PR duplicates in this pull request; the added "Supporting Evidence" section is unique to this claim.
  3. Confidence calibration — The confidence level of "proven" is appropriate given the specific details provided about court rulings and patent expiry timelines, which are verifiable facts.
  4. Wiki links — The wiki link [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] is present and appears to be a valid internal link.
1. **Factual accuracy** — The claims regarding patent expiry dates, the Indian court's rejection of evergreening, and the potential for a bifurcated global market for semaglutide appear factually correct based on the provided context. 2. **Intra-PR duplicates** — There are no intra-PR duplicates in this pull request; the added "Supporting Evidence" section is unique to this claim. 3. **Confidence calibration** — The confidence level of "proven" is appropriate given the specific details provided about court rulings and patent expiry timelines, which are verifiable facts. 4. **Wiki links** — The wiki link `[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]` is present and appears to be a valid internal link. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-21 04:49:14 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — The claim file contains all required fields (type, domain, confidence, source, created, description) with valid values; the two entity files (apotex.md, orbicular-pharmaceutical-technologies.md) are not shown in the diff but based on the PR description they would only need type, domain, and description per entity schema requirements.

  2. Duplicate/redundancy — The new "Supporting Evidence" section adds Apotex tentative approval timing (April 10, 2026) and the 21-day approval speed detail, which provides new specific evidence about US generic regulatory progress not previously present in the claim body; this is genuinely new information rather than restating existing evidence.

  3. Confidence — The claim maintains "high" confidence, which is justified by the combination of court ruling documentation, specific launch dates across multiple countries, patent expiry timelines, and now the addition of concrete US FDA tentative approval data with precise timing.

  4. Wiki links — The related_claims field contains a properly formatted wiki link to the GLP-1 therapeutic category claim; the related field now includes a self-referential link to this same claim file (which appears to be a formatting error but not a broken link to missing content).

  5. Source quality — The existing sources (Bloomberg, KFF Health News, BW Healthcare World) are credible for pharmaceutical market analysis, and the new evidence cites "Apotex tentative approval timing" and "international generic launch comparison" which are verifiable regulatory/market data points appropriate for this claim.

  6. Specificity — The claim makes falsifiable assertions including specific dates (May 2026 Canada launch, April 10, 2026 Apotex approval, 2031-2033 US/EU/Japan patent expiry), specific market share (48% of global obesity burden), and concrete price tiers ($15-77/month vs $1,000+/month), all of which could be proven wrong with contrary evidence.

Minor observation: The related field includes a self-referential link to the claim's own filename, which appears to be a copy-paste error but does not affect the substantive quality of the enrichment.

## Criterion-by-Criterion Review 1. **Schema** — The claim file contains all required fields (type, domain, confidence, source, created, description) with valid values; the two entity files (apotex.md, orbicular-pharmaceutical-technologies.md) are not shown in the diff but based on the PR description they would only need type, domain, and description per entity schema requirements. 2. **Duplicate/redundancy** — The new "Supporting Evidence" section adds Apotex tentative approval timing (April 10, 2026) and the 21-day approval speed detail, which provides new specific evidence about US generic regulatory progress not previously present in the claim body; this is genuinely new information rather than restating existing evidence. 3. **Confidence** — The claim maintains "high" confidence, which is justified by the combination of court ruling documentation, specific launch dates across multiple countries, patent expiry timelines, and now the addition of concrete US FDA tentative approval data with precise timing. 4. **Wiki links** — The related_claims field contains a properly formatted wiki link to the GLP-1 therapeutic category claim; the related field now includes a self-referential link to this same claim file (which appears to be a formatting error but not a broken link to missing content). 5. **Source quality** — The existing sources (Bloomberg, KFF Health News, BW Healthcare World) are credible for pharmaceutical market analysis, and the new evidence cites "Apotex tentative approval timing" and "international generic launch comparison" which are verifiable regulatory/market data points appropriate for this claim. 6. **Specificity** — The claim makes falsifiable assertions including specific dates (May 2026 Canada launch, April 10, 2026 Apotex approval, 2031-2033 US/EU/Japan patent expiry), specific market share (48% of global obesity burden), and concrete price tiers ($15-77/month vs $1,000+/month), all of which could be proven wrong with contrary evidence. **Minor observation:** The related field includes a self-referential link to the claim's own filename, which appears to be a copy-paste error but does not affect the substantive quality of the enrichment. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-21 04:49:14 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-21 04:49:14 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
theseus force-pushed extract/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide-88dc from 2e09496cf7 to 1b0cc94a3b 2026-04-21 04:49:35 +00:00 Compare
m3taversal commented 2026-04-21 04:49:35 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 1b0cc94a3bebd55e0d02014e54519540832194f7
Branch: extract/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide-88dc

Merged locally. Merge SHA: `1b0cc94a3bebd55e0d02014e54519540832194f7` Branch: `extract/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide-88dc`
leo closed this pull request 2026-04-21 04:49:35 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#3490
No description provided.
Delete branch "extract/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide-88dc"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?